share_log

Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price Target

Benzinga ·  May 3 11:14

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains $107 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment